百奥赛图,一家致力于临床前CRO服务和抗体药物研发的企业,在追求科创板上市的道路上遭遇了重重挑战。尽管公司声称实现了扭亏为盈,并且拥有自主研发的RenMice全人抗体小鼠平台这一核心技术,但深入分析其财务状况、市场表现以及内部治理结构后发现,这家公司正面临一系列严峻的问题,这些问题不仅威胁到其长期发展,也使得其科创板上市之路充满变数。从财务数据来看,虽然百奥赛图在2024年报告了3354万元的...
Source Link百奥赛图,一家致力于临床前CRO服务和抗体药物研发的企业,在追求科创板上市的道路上遭遇了重重挑战。尽管公司声称实现了扭亏为盈,并且拥有自主研发的RenMice全人抗体小鼠平台这一核心技术,但深入分析其财务状况、市场表现以及内部治理结构后发现,这家公司正面临一系列严峻的问题,这些问题不仅威胁到其长期发展,也使得其科创板上市之路充满变数。从财务数据来看,虽然百奥赛图在2024年报告了3354万元的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.